PTPA — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tautomycin (SCHEMBL83891)	1.00	5/20
Tautomycin (SCHEMBL21298444)	1.00	5/20
Tautomycin (SCHEMBL22965087)	1.00	5/20
Tautomycin (SCHEMBL23008659)	1.00	5/20
Tautomycin (SCHEMBL23008660)	1.00	5/20
SCHEMBL21298445	0.66	5/20
SCHEMBL24974804	0.62	5/20
SCHEMBL820638	0.41	3/20
SCHEMBL13901723	0.80	2/20
SCHEMBL3629702	0.73	2/20
SCHEMBL3622362	0.68	2/20
SCHEMBL21247385	0.67	2/20
SCHEMBL13837701	0.65	2/20
SCHEMBL21247131	0.65	2/20
SCHEMBL14825162	0.60	2/20
SCHEMBL3627300	0.59	2/20
SCHEMBL3629109	0.59	2/20
SCHEMBL13837658	0.58	2/20
SCHEMBL13837643	0.57	2/20
SCHEMBL14123489	0.56	2/20

Clinical trials — most relevant to PTPA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction	PHASE4	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
The T1DWATCH Study: a Screening for Type 1 Diabetes Autoantibodies in Children for Early Detection and Intervention.	nan	NOT_YET_RECRUITING
Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPA binder may also engage these)

Protein	Name	Similarity
P58389	—	0.996	P58389 →
Q2KJ44	—	0.981	Q2KJ44 →
Q28717	—	0.978	Q28717 →
Q803T2	—	0.962	Q803T2 →
Q04499	—	0.961	Q04499 →
Q5ZKY2	—	0.961	Q5ZKY2 →
E9Q4Z2	—	0.960	E9Q4Z2 →
A8DZH4	—	0.960	A8DZH4 →
Q9ER88	—	0.959	Q9ER88 →
Q8NHH9	—	0.959	Q8NHH9 →
Q5GFD9	—	0.958	Q5GFD9 →
B0KWH8	—	0.958	B0KWH8 →
B0KWC1	—	0.958	B0KWC1 →
O02810	—	0.957	O02810 →
ATG7	Ubiquitin-like modifier-activating enzyme ATG7	0.957	landscape →
P06762	—	0.957	P06762 →
Q9D906	—	0.957	Q9D906 →
ACACB	Acetyl-CoA carboxylase 2	0.957	landscape →
Q5I598	—	0.957	Q5I598 →
P14791	—	0.957	P14791 →
Q641Y5	—	0.956	Q641Y5 →
P97789	—	0.956	P97789 →
Q6WKZ8	—	0.956	Q6WKZ8 →
O08561	—	0.956	O08561 →
P23092	—	0.955	P23092 →
P35574	—	0.955	P35574 →
Q6R8G7	—	0.955	Q6R8G7 →
B1MTK1	—	0.955	B1MTK1 →
Q8IWV8	—	0.955	Q8IWV8 →
Q925B3	—	0.955	Q925B3 →